AMLX

Amylyx Pharmaceuticals Inc

28.86

Oct 30 • 3:59 PM ET +0.18 (0.63%)

28.86

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Drug Manufacturers - Specialty & Generic USA Mid NASD

Peers: RZLT XERS NBIX ALKS RYTM BCRX SUPN DNLI ASND PRAX

| Held by: VTI IWM VXF IWO IBB VTWO SCHA IHE XPH VHT

Scroll to Statements

Index	RUT
Market Cap	3.62B
Enterprise Value	3.38B
Income	-152.09M
Sales	0.00M
Book/sh	2.15
Cash/sh	2.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	136
IPO	Jan 07, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	13.44
P/C	14.45
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	12.12
Current Ratio	12.12
Debt/Eq	0.02
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-1.43
EPS next Y	-1.13
EPS next Q	-0.38
EPS this Y	2.21%
EPS next Y	24.33%
EPS next 5Y	49.92%
EPS past 3/5Y	19.94% -15.37%
Sales past 3/5Y	- -
EPS Y/Y TTM	42.67%
Sales Y/Y TTM	-100.00%
EPS Q/Q	16.00%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-8.06% -

Insider Own	15.31%
Insider Trans	-0.76%
Inst Own	85.70%
Inst Trans	0.52%
ROA	-66.25%
ROE	-74.73%
ROIC	-62.48%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	3.84%
SMA50	-6.58%
SMA200	43.73%
Trades

Shs Outstand	111.37M
Shs Float	106.30M
Short Float	12.46%
Short Ratio	5.95
Short Interest	13.25M
52W High	41.14 -29.85%
52W Low	10.83 166.48%
Volatility	4.59% 4.69%
ATR (14)	1.37
RSI (14)	51.89
Beta	-0.09
Rel Volume	0.44
Avg Volume	2.23M
Volume	989,447

Perf Week	6.10%
Perf Month	2.78%
Perf Quarter	43.08%
Perf Half Y	80.26%
Perf YTD	138.91%
Perf Year	105.41%
Perf 3Y	83.18%
Perf 5Y	-
Perf 10Y	-
Recom	1.25
Target Price	42.64
Prev Close	28.68
Price	28.86
Change %	0.63%

Consensus

Strong Buy

Avg. Price Target

$42.64

Implied Upside

+47.7%

Analysts11incl. previous ratings

Rating Distribution9 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Mar 03, 2026	Initiated	SStifel	Buy	$21	-27.2%
Jul 10, 2025	Resumed	GGoldman	Buy	$10	-65.3%
Jun 24, 2025	Initiated	GGuggenheim	Buy	$17	-41.1%
Jun 17, 2025	Initiated	CCitigroup	Buy	$12	-58.4%
May 30, 2025	Initiated	TTD Cowen	Buy
Apr 07, 2025	Upgrade	MMizuho	Neutral → Outperform	$7	-75.7%
Nov 18, 2024	Upgrade	RRobert W. Baird	Neutral → Outperform	$3 → $11	-61.9%
Oct 23, 2024	Upgrade	BBofA Securities	Neutral → Buy	$4.20 → $10	-65.3%
Mar 18, 2024	Downgrade	MMizuho	Buy → Neutral	$32 → $4	-86.1%
Mar 11, 2024	Downgrade	RRobert W. Baird	Outperform → Neutral	$37 → $4	-86.1%
Mar 11, 2024	Downgrade	LLeerink Partners	Outperform → Market Perform	$27 → $4	-86.1%
Mar 08, 2024	Downgrade	GGoldman	Buy → Neutral
Mar 08, 2024	Downgrade	EEvercore ISI	Outperform → In-line
Jan 03, 2024	Initiated	RRobert W. Baird	Outperform	$37	+28.2%
Dec 12, 2023	Initiated	DDeutsche Bank	Buy	$36	+24.7%
Jul 24, 2023	Upgrade	GGoldman	Neutral → Buy	$45 → $49	+69.8%
Mar 31, 2023	Initiated	MMizuho	Buy	$52	+80.2%
Jan 05, 2023	Initiated	BBofA Securities	Buy	$50	+73.3%
May 25, 2022	Initiated	CCitigroup	Buy	$21	-27.2%
Apr 01, 2022	Downgrade	GGoldman	Buy → Neutral	$36 → $10	-65.3%

Oct-06-26 08:00AM	Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek 2026 Annual Meeting (Business Wire)
Sep-23-26 09:00AM	Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum (Business Wire) -7.26%
Sep-08-26 09:00AM	Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference (Business Wire)
Aug-20-26 11:57PM	Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? (Stocktwits)
Aug-19-26 11:06PM	Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock (Business Wire) +9.94%
09:54PM	Loading…
Aug-18-26 09:54PM	Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today? (Stocktwits) +63.84%
05:31PM	AMLX Stock Clocks Best Day Ever After Positive Trial Data, Launches $350M Offering (Stocktwits)
04:01PM	Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock (Business Wire)
02:25PM	Amylyx stock surges after avexitide Phase 3 trial success (Quartz)
11:52AM	?? Under the Radar: Amylyx Stock Surges on Positive Trial Results (The Wall Street Journal)
10:45AM	Amylyx Pharmaceuticals Phase 3 LUCIDITY Trial Meets Primary Endpoint for Avexitide (InvestorsHub)
10:10AM	AMLX Stock Heads For Best Day In Nearly Four Years Retail Sees Near 70% Upside Potential From Current Levels (Stocktwits)
07:23AM	Amylyx Stock Surges 21% After GLP-1 Drug Succeeds in Phase 3 Trial (Barrons.com)
07:00AM	Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia (Business Wire)
03:02AM	Amylyxs bet on a GLP-1 blocker pays off (BioPharma Dive)
07:21PM	Loading…
Aug-17-26 07:21PM	Why Is AMLX Stock Popping 14% After Hours? (Stocktwits)
04:01PM	Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 (Business Wire)
Aug-06-26 03:01PM	Amylyx Pharmaceuticals Inc (AMLX) (Q2 2026) Earnings Call Highlights: Advancing Toward Pivotal ... (GuruFocus.com) +10.71%
07:00AM	Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results (Business Wire)
Aug-03-26 09:00AM	Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 (Business Wire)
Jul-03-26 12:15PM	Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
May-07-26 07:00AM	Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results (Business Wire) -5.35%
May-05-26 07:00AM	Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia (Business Wire)
Apr-30-26 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire)
Apr-09-26 07:54PM	Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire) -5.54%
Apr-08-26 09:00AM	Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-24-26 07:00AM	Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia (Business Wire)
Mar-04-26 08:02PM	Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) +6.66% -6.31%
03:57AM	Amylyx Pharmaceuticals Says 2026 Could Be Transformative Ahead of Avexitide Phase 3 Readout (MarketBeat)
Mar-03-26 11:18AM	Amylyx Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat) -7.78%
07:00AM	Loading…
07:00AM	Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-26-26 09:00AM	Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences (Business Wire) +6.19%
Feb-24-26 09:00AM	Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 (Business Wire) +5.83%
Jan-29-26 05:05PM	HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Jan-19-26 08:01AM	Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders (Insider Monkey)
Jan-10-26 02:57PM	Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases (Insider Monkey)
Jan-09-26 07:16AM	Amylyx selects AMX0318 as development candidate for PBH (TipRanks)
Jan-08-26 07:00AM	Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S (Business Wire)
Dec-12-25 04:35AM	Amylyx pins its next hopes on a niche drug in the obesity space (Pharma Voice)
Dec-05-25 09:00AM	Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial (Business Wire)
Nov-28-25 06:40PM	HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Nov-10-25 09:40AM	Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-06-25 02:12PM	Amylyx Pharmaceuticals Inc (AMLX) Q3 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com) -5.89%
07:00AM	Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 09:00AM	Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Oct-30-25 09:00AM	Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
Oct-27-25 12:20PM	Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-26-25 06:16AM	BofA Securities Lifts Amylyx Pharmaceuticals Inc. (AMLX) Price Target Amid Bolstered Balance Sheet (Insider Monkey)
Oct-24-25 12:00PM	What Makes Amylyx Pharmaceuticals, Inc. (AMLX) a Strong Momentum Stock: Buy Now? (Zacks)
09:55AM	Wall Street Analysts See a 29.28% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High? (Zacks)
09:40AM	Has Amylyx Pharmaceuticals (AMLX) Outpaced Other Medical Stocks This Year? (Zacks)
Oct-16-25 04:43PM	Is AMLX Stock a Solid Choice Right Now? (Zacks)
Sep-10-25 12:06AM	Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock (Business Wire) +12.56%
Sep-09-25 04:01PM	Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Aug-27-25 12:35PM	Amylyx culls rare neurological disorder programme after trial failure (Pharmaceutical Technology)
12:24PM	Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial (Benzinga)
07:22AM	Amylyx drug comes up short; Sanofi names new CMO (BioPharma Dive)
07:00AM	Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP) (Business Wire)
Aug-19-25 12:07AM	H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm 'Buy' Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) (Insider Monkey)
Aug-07-25 07:00AM	Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-31-25 09:00AM	Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-15-25 08:58AM	Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion (Insider Monkey)
Jul-14-25 11:52AM	Amylyx presents new exploratory analyses from avexitide trials for PBH (Clinical Trials Arena) +9.51%
Jul-13-25 05:00PM	Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 (Business Wire)
Jul-08-25 07:00AM	Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025 (Business Wire)
Jun-27-25 07:56AM	Why Shares in Amylyx Pharmaceuticals Soared This Week (Motley Fool)
Jun-25-25 03:27AM	After myriad failures, a new wave of ALS drugs approaches (Pharma Voice)
Jun-24-25 12:46PM	Amylyx Pharmaceuticals Gains FDA Fast Track for ALS Drug AMX0114 (Insider Monkey) +27.69%
Jun-03-25 07:00AM	Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis (Business Wire)
May-21-25 07:00AM	Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences (Business Wire)
May-20-25 09:55AM	Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High? (Zacks)
May-12-25 07:00AM	Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome (Business Wire)
May-09-25 03:12AM	Amylyx Pharmaceuticals Inc (AMLX) Q1 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
May-08-25 07:00AM	Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results (Business Wire) -5.95%
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
08:00AM	Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences (Business Wire)
May-01-25 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire)
06:06AM	Amylyx doses first subject in trial of post-bariatric hypoglycaemia treatment (Clinical Trials Arena)
Apr-30-25 07:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia (Business Wire)
Apr-16-25 11:22AM	Is Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Apr-11-25 08:11AM	Amgen says Imdelltra extended survival; Parker Institute adds new leaders (BioPharma Dive)
Apr-10-25 07:03AM	First subject dosed in Amylyxs Phase I trial of ALS therapy (Clinical Trials Arena)
Apr-09-25 07:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis (Business Wire) +5.44%
Apr-02-25 09:00AM	Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire) +13.17%
Mar-27-25 10:17AM	Is Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-05-25 10:01AM	Amylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +11.63%
Mar-04-25 06:00AM	Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Mar-03-25 07:18AM	Amylyx Pharmaceuticals Inc (AMLX) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) -8.54%
Feb-25-25 09:00AM	Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences (Business Wire)
Feb-24-25 09:00AM	Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 (Business Wire) -9.09%
Feb-10-25 09:00AM	Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-31-25 12:00PM	Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-22-25 05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive)
Jan-21-25 09:00AM	Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (Business Wire)
Jan-10-25 08:26AM	Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire) -7.16%
Jan-09-25 07:30PM	Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Jan-06-25 09:00AM	Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer (Business Wire) -5.54%
Dec-30-24 02:52PM	Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-05-24 07:35AM	Amylyx announces design of LUCIDITY clinical trial (TipRanks) -5.51%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MILNE GEORGE M JR	Director	Oct 05 '26	Sale	27.70	30,000	830,904	782,881	Oct 07 04:00 PM
GEORGE MILNE	Director	Oct 05 '26	Proposed Sale	27.79	100,000	2,779,000		Oct 05 04:38 PM
Bedrosian Camille L	Chief Medical Officer	Sep 10 '26	Sale	32.40	10,028	324,868	278,064	Sep 14 04:00 PM
FRATES JAMES M	Chief Financial Officer	Sep 10 '26	Sale	32.36	10,810	349,821	233,625	Sep 14 04:00 PM
Mazzariello Gina	Chief Legal Officer	Sep 10 '26	Sale	32.46	9,536	309,506	190,838	Sep 14 04:00 PM
Klee Justin B.	Co-Chief Executive Officer	Sep 10 '26	Sale	32.18	30,464	980,263	3,613,056	Sep 14 04:00 PM
Cohen Joshua B	Co-Chief Executive Officer	Sep 10 '26	Sale	32.19	30,464	980,504	3,613,123	Sep 14 04:00 PM
Klee Justin B.	Officer	Sep 10 '26	Proposed Sale	32.18	30,464	980,264		Sep 11 04:01 PM
Frates James M	Officer	Sep 10 '26	Proposed Sale	32.36	10,810	349,821		Sep 11 04:01 PM
Bedrosian Camille L	Officer	Sep 10 '26	Proposed Sale	32.40	10,028	324,868		Sep 11 04:01 PM
Cohen Joshua B	Officer	Sep 10 '26	Proposed Sale	32.19	30,464	980,504		Sep 11 04:01 PM
Mazzariello Gina	Officer	Sep 10 '26	Proposed Sale	32.46	9,536	309,506		Sep 11 04:01 PM
Firestone Karen	Director	Aug 31 '26	Option Exercise	3.40	50,000	170,250	116,900	Sep 02 04:00 PM
Mazzariello Gina	Chief Legal Officer	Jul 09 '26	Sale	18.32	15,000	274,746	194,090	Jul 13 04:00 PM
Mazzariello Gina	Chief Legal Officer	Jul 10 '26	Sale	17.61	15,000	264,122	179,090	Jul 13 04:00 PM
GINA MAZZARIELLO	Officer	Jul 09 '26	Proposed Sale	17.88	30,000	536,400		Jul 09 04:26 PM
Firestone Karen	Director	May 21 '26	Buy	13.51	3,800	51,338	66,900	May 26 04:00 PM
Klee Justin B.	Co-Chief Executive Officer	Mar 02 '26	Sale	14.47	29,282	423,760	3,334,616	Mar 04 04:00 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 02 '26	Sale	14.48	29,282	424,120	3,334,683	Mar 04 04:00 PM
Bedrosian Camille L	Chief Medical Officer	Mar 02 '26	Sale	14.58	6,461	94,205	169,295	Mar 04 04:00 PM
FRATES JAMES M	Chief Financial Officer	Mar 02 '26	Sale	14.52	7,909	114,851	165,638	Mar 04 04:00 PM
Mazzariello Gina	Chief Legal Officer	Mar 02 '26	Sale	14.52	6,844	99,378	134,430	Mar 04 04:00 PM
Klee Justin B.	Officer	Mar 02 '26	Proposed Sale	14.47	29,282	423,760		Mar 02 04:30 PM
Frates James M	Officer	Mar 02 '26	Proposed Sale	14.52	7,909	114,852		Mar 02 04:30 PM
Bedrosian Camille L	Officer	Mar 02 '26	Proposed Sale	14.58	6,461	94,205		Mar 02 04:30 PM
Cohen Joshua B	Officer	Mar 02 '26	Proposed Sale	14.48	29,282	424,120		Mar 02 04:30 PM
Mazzariello Gina	Officer	Mar 02 '26	Proposed Sale	14.52	6,844	99,379		Mar 02 04:30 PM
Mazzariello Gina	Chief Legal Officer	Feb 23 '26	Sale	14.14	3,419	48,352	141,274	Feb 25 04:00 PM
Mazzariello Gina	Officer	Feb 23 '26	Proposed Sale	14.14	3,419	48,352		Feb 23 04:25 PM
FRATES JAMES M	Chief Financial Officer	Feb 02 '26	Sale	14.65	3,557	52,097	173,547	Feb 04 04:05 PM
Cohen Joshua B	Co-Chief Executive Officer	Feb 02 '26	Sale	14.68	15,500	227,593	3,363,965	Feb 04 04:05 PM
Mazzariello Gina	Chief Legal Officer	Feb 02 '26	Sale	14.65	3,448	50,516	144,693	Feb 04 04:05 PM
Klee Justin B.	Co-Chief Executive Officer	Feb 02 '26	Sale	14.69	15,500	227,618	3,363,898	Feb 04 04:05 PM
Klee Justin B.	Officer	Feb 02 '26	Proposed Sale	14.68	15,500	227,617		Feb 02 04:10 PM
Cohen Joshua B	Officer	Feb 02 '26	Proposed Sale	14.68	15,500	227,593		Feb 02 04:10 PM
Mazzariello Gina	Officer	Feb 02 '26	Proposed Sale	14.65	3,448	50,515		Feb 02 04:10 PM
Frates James M	Officer	Feb 02 '26	Proposed Sale	14.65	3,557	52,097		Feb 02 04:10 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 15 '26	Option Exercise	7.57	197,182	1,492,668	3,514,814	Jan 20 09:46 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 16 '26	Option Exercise	7.57	2,818	21,332	3,381,439	Jan 20 09:46 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 15 '26	Sale	13.59	136,193	1,850,795	3,378,621	Jan 20 09:46 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 16 '26	Sale	13.83	1,974	27,299	3,379,465	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 15 '26	Option Exercise	7.57	197,153	1,492,448	3,514,739	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 16 '26	Option Exercise	7.57	2,847	21,552	3,381,393	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 15 '26	Sale	13.58	136,193	1,849,869	3,378,546	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 16 '26	Sale	13.89	1,995	27,701	3,379,398	Jan 20 09:46 PM
JUSTIN KLEE	Director	Jan 16 '26	Proposed Sale	13.52	1,995	26,972		Jan 16 04:05 PM
JOSHUA COHEN	Director	Jan 16 '26	Proposed Sale	13.52	1,974	26,688		Jan 16 04:03 PM
JOSHUA COHEN	Director	Jan 15 '26	Proposed Sale	14.07	136,193	1,916,236		Jan 15 04:17 PM
JUSTIN KLEE	Director	Jan 15 '26	Proposed Sale	14.07	136,193	1,916,236		Jan 15 04:14 PM
FRATES JAMES M	Chief Financial Officer	Jan 06 '26	Sale	11.11	3,326	36,954	177,104	Jan 08 04:05 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 06 '26	Sale	11.09	7,715	85,596	3,317,632	Jan 08 04:05 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 06 '26	Sale	11.09	7,715	85,589	3,317,586	Jan 08 04:05 PM
Frates James M	Officer	Jan 06 '26	Proposed Sale	11.11	3,326	36,954		Jan 06 04:05 PM
Klee Justin B.	Officer	Jan 06 '26	Proposed Sale	11.09	7,715	85,590		Jan 06 04:05 PM
Cohen Joshua B	Officer	Jan 06 '26	Proposed Sale	11.09	7,715	85,597		Jan 06 04:04 PM
Firestone Karen	Director	Dec 23 '25	Buy	12.45	8,100	100,845	63,100	Dec 23 08:48 PM
Bedrosian Camille L	Chief Medical Officer	Dec 01 '25	Sale	14.35	6,580	94,418	175,756	Dec 03 04:39 PM
Bedrosian Camille L	Officer	Dec 01 '25	Proposed Sale	14.35	6,580	94,419		Dec 01 04:05 PM

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx's pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Co-FounderMr. Joshua B. Cohen

Co-CEO & DirectorMr. Justin B. Klee

Chief Financial OfficerMr. James M. Frates M.B.A.

Chief Medical OfficerDr. Camille L. Bedrosian M.D.

Chief Technical Operations OfficerMr. Tom Holmes

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMLX

Amylyx Pharmaceuticals Inc

Upgrade your Finviz experience